临床荟萃

• 论著 • 上一篇    下一篇

利伐沙班对合并心功能不全的高龄非瓣膜性心房颤动疗效及安全性

  

  1. 临夏回族自治州人民医院 心内科,甘肃 临夏  731100
  • 出版日期:2020-05-20 发布日期:2020-04-27
  • 通讯作者: 马进才,Email: vde2kw@163.com

Efficacy and safety of rivaroxaban in elderly patients with nonvalvular atrial  fibrillation complicated with cardiac insufficiency

  1. Department of  Cardiovascular  Medicine,  People's Hospital of Linxia Hui  Autonomous Prefecture,  Linxia 731100,  China
  • Online:2020-05-20 Published:2020-04-27
  • Contact: Corresponding author: Ma Jincai, Email:vde2kw@163.com

摘要: 目的  分析利伐沙班对合并心功能不全的高龄非瓣膜性心房颤动(nonvalvular atrial fibrillation,NVAF)患者临床疗效及安全性。方法  随机连续纳入2016年1月至2020年1月间就诊于我院合并心功能不全的高龄NVAF患者182例,随机分为两组,其中91例患者应用利伐沙班抗凝归为观察组,余91例应用华法林抗凝归为对照组。随访记录两组抗凝期间血栓事件、出血等不良反应以及凝血功能和心功能情况。结果  观察组总出血事件显著低于对照组;观察组治疗后N末端B型利钠肽前体(NTproBNP)较对照组显著下降;COX风险模型发现,年龄及华法林是不良事件的危险因素。结论  利伐沙班对于合并心功能不全的高龄NVAF患者疗效不劣于华法林,但安全性显著高于华法林。

关键词: 心房颤动, 非瓣膜性, 利伐沙班, 心功能不全, 高龄, 疗效, 安全性

Abstract: Objective  To analyze the clinical efficacy and safety of rivaroxabanin elderly patients with nonvalvular atrial fibrillation (NVAF) complicated with cardiac insufficiency. Methods  A total of 182 elderly NVAF patients complicated with cardiac insufficiency who were admitted to the hospital from January 2016 to January 2020 were enrolled. The patients were randomly divided into two groups,  91 cases were selected for rivaroxaban  anticoagulation as observation group,  and other 91 cases were treated with warfarin anticoagulation as control group. The adverse events including thrombotic events,  hemorrhage,  and coagulation, as well as the coagulation function and cardiac function were recorded during the followup in two groups. Results  The total bleeding events in observation group were  significantly lower than those in control group. NTproBNP  of observation group significantly decreased compared with that of control group after  treatment. COX risk model found  that the age and warfarin were risk factors for adverse events. Conclusion  Rivaroxaban is not inferior to warfarin in treating the elderly NVAF  patients complicated with cardiac insufficiency,  but  its  safety is significantly higher than that of warfarin.

Key words: atrial fibrillation, nonvalvular; , rivaroxaban, cardiac insufficiency; , the elderly; , efficacy, safety